Kenvue Stock Overview and Financial Analysis Report

Kenvue is a publicly traded company listed on the New York Stock Exchange (NYSE) under the ticker symbol KENV. It's a relatively new player in the market, having gone public in 2022.

The company's primary focus is on developing and commercializing innovative medical devices. Their product portfolio includes a range of diagnostic and surgical tools.

As of the latest available data, Kenvue's market capitalization stands at approximately $10 billion. This figure is subject to change based on market fluctuations and company performance.

Kenvue's financial performance has been impressive, with revenue growth of over 20% in the past year. This is a testament to the company's innovative products and expanding market reach.

For more insights, see: The New York Times Company

The current state of Kenvue stock is a concerning one, with a decline of -33.91% in recent times. This significant drop in value has left many investors wondering what's next for the company.

The previous close for Kenvue stock was 16.26, indicating a substantial loss from its previous value. This decline is likely to have a ripple effect on the overall market.

The open price for the day was 16.28, which is just a slight increase from the previous close. However, this small gain is overshadowed by the overall decline in value.

Here are some key statistics that highlight the current state of Kenvue stock:

The market capitalization of Kenvue stock is a staggering 27.078 billion, indicating a significant presence in the market. However, this large market cap is not enough to cushion the blow of the recent decline.

The beta value of Kenvue stock is 0.67, indicating a moderate level of risk associated with investing in the company. This is a crucial factor to consider for investors who are risk-averse.

The price-to-earnings ratio (PE Ratio) of Kenvue stock is 18.81, which is slightly higher than the industry average. This suggests that investors are paying a premium for the company's stock.

The earnings per share (EPS) for Kenvue stock is 0.75, which is a relatively low value. This indicates that the company is not generating significant profits at present.

The earnings date for Kenvue stock is set for November 6, 2025, which is a date to watch for investors who are interested in the company's financial performance.

Discover more: General American Investors Company

Kenvue is the world's largest pure-play consumer health company by revenue, generating $15 billion in annual sales.

The company has a strong portfolio of 15 priority brands, including Tylenol, Nicorette, Listerine, and Zyrtec, which are expected to drive future growth.

Kenvue operates through three business segments: Self Care, Skin Health and Beauty, and Essential Health.

The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation products.

Kenvue has the freedom to allocate capital and invest as a standalone entity, which is expected to lead to increased innovation and growth.

The company has already shown its commitment to innovation with the launch of products like Nicorette QuickMist SmartTrack spray and Zyrtec AllergyCast app.

The financial health of Kenvue stock is a crucial aspect to consider for any investor. Total cash on hand is a significant $1.07B as of the most recent quarter.

The company's debt-to-equity ratio is a relatively high 81.49%, indicating a substantial amount of debt compared to its equity. This can be a concern for investors, as it may impact the company's ability to take on more debt in the future.

A different take: Debt Consolidation Capital One

Kenvue's levered free cash flow is a respectable $1.92B as of the trailing twelve months, suggesting that the company has a strong ability to generate cash from its operations. This is a positive sign for investors, as it indicates that the company has the resources it needs to invest in its business and pay dividends.

Here are some key financial metrics for Kenvue compared to its peers:

Kenvue's return on assets is a solid 6.73% as of the most recent quarter, indicating that the company is generating a respectable amount of profit from its assets. This is a positive sign for investors, as it suggests that the company has a strong ability to generate revenue from its operations.

Explore further: Oaktree Capital Assets under Management

Let's take a closer look at the financial position and cash flow of a company. The total cash on hand is a whopping $1.07 billion, which is a great indicator of a company's liquidity.

For your interest: American Express Blue Cash Benefits

This amount of cash can help a company weather financial storms and take advantage of new opportunities. The total debt to equity ratio is a bit higher at 81.49%, which means the company is relying more on debt than equity to fund its operations.

A quick ratio of 0.66 suggests that the company's liquid assets are covering about 66% of its current liabilities. The current ratio is 1.00, which means the company's current assets are equal to its current liabilities.

The interest coverage ratio is 3.71, which means the company's earnings before interest and taxes are 3.71 times its interest expenses. This is a relatively low interest coverage ratio, indicating that the company may be struggling to meet its interest payments.

In terms of cash flow, the levered free cash flow is $1.92 billion, which is a strong indicator of a company's ability to generate cash from its operations.

On a similar theme: How Much Money Can I Withdraw from Wells Fargo Atm

Financial analysis is a crucial aspect of understanding a company's performance. It helps investors and stakeholders make informed decisions about their investments.

Looking at the profitability metrics, we can see that KVUE has a Return on Assets (Normalized) of 6.73%. This means that for every dollar invested, KVUE generates 6.73 cents in profit.

KMB stands out with a Return on Equity (Normalized) of 244.17%, significantly higher than KVUE and PG. This indicates that KMB is generating a substantial amount of profit from its equity.

PG's Return on Equity (Normalized) is 33.03%, which is lower than KMB but still respectable.

Here are the normalized profitability metrics for KVUE, KMB, and PG in a quick glance:

These metrics provide a snapshot of each company's profitability, helping us understand their financial health and potential for growth.

KVUE is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue.

The company has a strong portfolio of well-known brands, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena, which are the global leaders in their respective segments thanks to their strong brand power.

KVUE operates in various silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health.

The company spun off from Johnson & Johnson's consumer segment and went public in May 2023, giving it the freedom to allocate capital and invest as a standalone entity.

KVUE's strong brand power has helped it maintain a leading position in a fragmented industry with intense competition and changing consumer preferences.

KVUE has a research and development budget of roughly 3% of sales, which is on par with some of its wide-moat competitors, to launch innovative products, such as the Nicorette QuickMist SmartTrack spray and Zyrtec AllergyCast app.

Explore further: Johnson & Johnson

The market data for Kenvue stock is a crucial aspect to consider. Kenvue stock has experienced a slight decline, with a -0.08 (-0.37%) drop.

In fact, this is not the only time Kenvue stock has seen a decrease. After-market trading saw a -0.01 (-0.05%) drop, indicating a slight volatility in the market.

As you can see from the data, the consumer products - staples industry is the sector in which Kenvue operates. This is an important factor to consider when evaluating the stock's performance.

Expand your knowledge: Flagstar Bank Data Breach 2023

The valuation of Kenvue stock is a crucial aspect to consider when deciding whether to invest. Market Cap stands at 30.19B.

Kenvue's Enterprise Value is significantly higher at 37.86B, indicating a substantial market presence. The Trailing P/E ratio is 20.97, which may be a concern for some investors.

However, the Forward P/E ratio is lower at 14.20, suggesting a potential for growth in the future. The PEG Ratio (5yr expected) is 0.79, which is lower than some of its competitors.

Here's a comparison of Kenvue's valuation metrics with some of its peers:

As we can see, Kenvue's valuation metrics are relatively comparable to its peers. However, it's essential to note that valuation is just one aspect to consider when making investment decisions.

If you're considering investing in Kenvue stock, here's what you need to know. The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.

It's essential to understand that the involvement of an activist investor can bring about significant changes in a company's strategy and operations. This could potentially lead to increased revenue and profitability for Kenvue.

One thing to keep in mind is that activist investors often push for changes that benefit shareholders, which can be a good thing for investors.

Expand your knowledge: How Are Stock Speculators Different from Stock Investors